SCHEMBL5886809

SCHEMBL5886809

Cc1nc(N2CCN(c3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.41
HPGD P15428 5/20 0.41
TSHR P16473 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
KMT2A Q03164 2/20 0.39
HSD17B10 Q99714 5/20 0.39
CYP1A2 P05177 3/20 0.39
CASP1 P29466 3/20 0.39
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
CCND2 P30279 1/20 0.38
CCND3 P30281 1/20 0.38
CASP7 P55210 2/20 0.38
CLK4 Q9HAZ1 1/20 0.38
NPC1 O15118 3/20 0.37
METAP1 P53582 1/20 0.37
POLB P06746 1/20 0.37
GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886717 0.92 MEN1 (0.40) ALDH1A1HPGDTSHRSMN1; SMN2MAPT
SCHEMBL5887125 0.91 RAB9A (0.42) ALDH1A1SMN1; SMN2MAPTHTTKMT2A
SCHEMBL5887121 0.89 GPR119 (0.41) ALDH1A1TSHRSMN1; SMN2MAPTHTT
SCHEMBL5886798 0.87 RXRA (0.47) ALDH1A1HPGDTSHRSMN1; SMN2MAPT
SCHEMBL5886729 0.86 ALDH1A1 (0.37) ALDH1A1HPGDCYP1A2RXRA
SCHEMBL5887084 0.85 ALDH1A1 (0.42) ALDH1A1HPGDTSHRSMN1; SMN2MAPT
SCHEMBL5886830 0.85 ALDH1A1 (0.42) ALDH1A1HPGDTSHRSMN1; SMN2MAPT
SCHEMBL5886964 0.81 MAPK8 (0.45) ALDH1A1SMN1; SMN2MAPTKMT2APOLB
SCHEMBL5887542 0.81 MAPK8 (0.45) ALDH1A1HPGDTSHRSMN1; SMN2MAPT
SCHEMBL5886891 0.80 TP53 (0.44) ALDH1A1SMN1; SMN2MAPTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP ALDH1A1 1860/4885HPGD 1371/4885TSHR 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.